AdAlta Ltd. (1AD) Price & Analysis

Compare

5 Followers

1AD Stock Chart & Stats

AU$0.01

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.01

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.01 - AU$0.02

Previous CloseN/A

Volume270.05K

Average Volume (3M)574.71K

Market Cap

AU$10.20M

Enterprise ValueAU$984.26K

Total Cash (Recent Filing)AU$1.31M

Total Debt (Recent Filing)AU$1.77M

Price to Earnings (P/E)―

Beta1.22

Next Earnings

Mar 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding2,549,669,000

10 Day Avg. Volume957,709

30 Day Avg. Volume574,705

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)-4.36

Price to Sales (P/S)3.86

P/FCF Ratio-0.89

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Innovative Technology PlatformAdAlta's proprietary i-body platform technology offers a unique approach to developing biologics, potentially providing a competitive edge in the biotechnology sector by addressing unmet medical needs in oncology and other areas.

Strategic PartnershipsCollaborative agreements and licensing deals with established pharmaceutical companies enhance AdAlta's research capabilities and provide financial support through milestone payments and royalties, fostering long-term growth and innovation.

Research Grants And FundingAccess to government grants and research funding supports AdAlta's innovative therapeutic research, providing a stable financial resource that aids in the development of new drug candidates and strengthens its market position.

Bears Say

Declining RevenueA significant decline in revenue growth, as indicated by a -30.42% rate, poses a challenge to AdAlta's financial stability and limits its ability to invest in future growth opportunities, impacting long-term sustainability.

High Leverage And Negative EquityHigh leverage and negative equity signal financial instability, limiting AdAlta's ability to secure additional financing and invest in strategic initiatives, potentially hindering long-term operational success.

Negative Cash FlowNegative cash flow growth indicates difficulties in generating sufficient cash from operations, which can constrain AdAlta's ability to fund research and development activities, impacting its capacity to innovate and expand.

AdAlta Ltd. News

AdAlta outlines ‘East to West’ strategy to expand CAR-T access across Australia and SE Asia

AdAlta Ltd. ( ($AU:1AD) ) has shared an announcement. AdAlta Limited, a clinical-stage Australian biotech specialising in cellular...

15d ago

1AD

AdAlta Completes Share and Option Issue to Sophisticated Investors

AdAlta Ltd. ( ($AU:1AD) ) has shared an announcement. AdAlta Limited has completed a capital raising via a...

20d ago

1AD

AdAlta Seeks ASX Quotation for New Shares and Options

AdAlta Ltd. ( ($AU:1AD) ) has shared an update. AdAlta Limited has applied to the ASX for quotation...

20d ago

1AD

AdAlta Seeks ASX Quotation for 240m New Shares and 120m Options

AdAlta Ltd. ( ($AU:1AD) ) has issued an update. AdAlta Ltd has lodged an application with the ASX...

20d ago

1AD

AdAlta’s AdCella Gains Tailwind from FDA Shift as BZDS1901 Milestone and R&D Rebate Strengthen ‘East to West’ Strategy

AdAlta Ltd. ( ($AU:1AD) ) has issued an update. AdAlta’s cellular immunotherapy subsidiary AdCella is set to benefit...

29d ago

1AD

AdAlta outlines “East to West” strategy and first-in-class CAR-T program

AdAlta Ltd. ( ($AU:1AD) ) has shared an update. AdAlta Limited has released an investor presentation outlining its...

1M ago

1AD

AdAlta Schedules Investor Webinar on CAR-T Deal and ‘East to West’ Strategy

AdAlta Ltd. ( ($AU:1AD) ) just unveiled an update. AdAlta will host a virtual investor webinar on 15...

1M ago

1AD

AdAlta Plans Significant New Share and Option Issue on ASX

The latest update is out from AdAlta Ltd. ( ($AU:1AD) ). AdAlta Limited has announced a proposed placement...

1M ago

1AD

AdAlta Plans Major Capital Raising via Share and Option Issue

AdAlta Ltd. ( ($AU:1AD) ) just unveiled an update. AdAlta Limited, listed on the ASX under the code...

1M ago

1AD

AdAlta Secures A$1.2m Placement to Accelerate ‘East to West’ CAR-T Strategy

AdAlta Ltd. ( ($AU:1AD) ) has issued an announcement. AdAlta has secured binding commitments from a restricted group...

1M ago

1AD

1AD FAQ

What was AdAlta Ltd.’s price range in the past 12 months?

AdAlta Ltd. lowest share price was AU$0.01 and its highest was AU$0.02 in the past 12 months.

What is AdAlta Ltd.’s market cap?

AdAlta Ltd.’s market cap is AU$10.20M.

When is AdAlta Ltd.’s upcoming earnings report date?

AdAlta Ltd.’s upcoming earnings report date is Mar 02, 2026 which is in 12 days.

How were AdAlta Ltd.’s earnings last quarter?

AdAlta Ltd. released its earnings results on Aug 26, 2025. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.003.

Is AdAlta Ltd. overvalued?

According to Wall Street analysts AdAlta Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AdAlta Ltd. pay dividends?

AdAlta Ltd. does not currently pay dividends.

What is AdAlta Ltd.’s EPS estimate?

AdAlta Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AdAlta Ltd. have?

AdAlta Ltd. has 2,549,669,000 shares outstanding.

What happened to AdAlta Ltd.’s price movement after its last earnings report?

AdAlta Ltd. reported an EPS of -AU$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of AdAlta Ltd.?

Currently, no hedge funds are holding shares in AU:1AD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

AdAlta Ltd. Stock Smart Score

Neutral

Insider Transactions

Bought Shares

Worth AU$8.8K over
the Last 3 Months

Fundamentals

Return on Equity

-628.72%

Trailing 12-Months

Asset Growth

-61.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

AdAlta Ltd.

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd. to develop CAR-T cell products against various solid tumor antigens. AdAlta Limited was incorporated in 2006 and is headquartered in Bundoora, Australia.